Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use

10 Dec 2022 Trial design presented at the 45th Annual San Antonio Breast Cancer Symposium.
02 Dec 2022 Status changed from recruiting to withdrawn prior to enrolment.
13 Apr 2022 Trial design, presented at the 113th Annual Meeting of the American Association for Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com